Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study

Autor: Hervé Dombret, Patrice Chevallier, Jean-Pierre Marolleau, Jamile Frayfer, Nicolas Boissel, Emmanuelle Tavernier, Caroline Bonmati, Véronique Lhéritier, Mathilde Hunault-Berger, Marie Balsat, Denis Caillot, Yves Chalandon, Thomas Pabst, Norbert Ifrah, Sylvain Chantepie, Françoise Huguet, Noémie de Gunzburg, Corentin Orvain, Victoria Cacheux

Publikováno v: Blood, Vol. 136, No 3 (2020) pp. 328-338
Blood
Blood, American Society of Hematology, 2020, 136 (3), pp.328-338. ⟨10.1182/blood.2020004919⟩
Blood, 2020, 136 (3), pp.328-338. ⟨10.1182/blood.2020004919⟩

International audience; Patients undergoing treatment for acute lymphoblastic leukemia (ALL) are at risk for thrombosis, in part due to the use of L-asparaginase (L-ASP). Antithrombin (AT) replacement has been suggested to prevent VTE and thus might

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94b43757ed21009cab537e5d08af26fc
https://archive-ouverte.unige.ch/unige:154831

Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study

Autor: Emmanuelle Tavernier, Denis Caillot, Yves Chalandon, Sylvain Chantepie, Françoise Huguet, Thomas Pabst, Norbert Ifrah, Corentin Orvain, Nicolas Boissel, Hervé Dombret, Patrice Chevallier, Marie Balsat, Mathilde Hunault-Berger, Véronique Lhéritier, Jamile Frayfer, Victoria Cacheux, Noémie de Gunzburg, Jean-Pierre Marolleau, Caroline Bonmati

Publikováno v: Blood
Blood, 2016, 128 (22), ⟨10.1182/blood.V128.22.2776.2776⟩

Background: Patients undergoing treatment for acute lymphoblastic leukemia (ALL) are at risk for thrombosis, in part due to the use of L-asparaginase (L-ASP) and subsequent antithrombine (AT) deficiency. Previous reports showed that patients with ven

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28117a693deda1d8b56cef9d86cc8f0b
https://hal-u-picardie.archives-ouvertes.fr/hal-03605054

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

Autor: Sylvie Chevret, Pierre Fenaux, Xavier Thomas, Ollivier Legrand, Lauris Gastaud, Oumedaly Reman, Jean-Noël Bastie, Philippe Rousselot, Dominique Bordessoule, Maud Janvier, Thierry de Revel, Nathalie Contentin, Stephanie Foucault-Haiat, Estelle Henry, Marc A. Simon, Pascal Turlure, Olivier Hermine, Isabelle Plantier, Brigitte Dupriez, Noémie de Gunzburg, Claude Preudhomme, Laurent Sutton, Céline Berthon, Claude Gardin, Stéphane de Botton, Jean Pierre Marolleau, Hervé Dombret, Christine Terré, Emmanuel Raffoux, Sylvie Castaigne, Cécile Pautas

Publikováno v: ResearcherID

Abstract 6 Aim. GO is a potent antibody-directed chemotherapy against CD33 antigen. Two MRC and SWOG Phase 3 studies have compared standard CT alone or combined with one single GO infusion (at 3 and 6 mg/m2, respectively) in younger adults with AML w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fffb88f31d2561d6d8fa676f3609a30a
https://doi.org/10.1182/blood.v118.21.6.6

Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.

Autor: Trinquand A; Amélie Trinquand, Raouf Ben Abdelali, Etienne Lengliné, Noémie De Gunzburg, Ludovic Lhermitte, Jonathan Bond, Agnès Buzyn, Elizabeth Macintyre, and Vahid Asnafi, University Paris Descartes, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR)-8147, and Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker-Enfants Malades; Jérôme Lambert, UMR-S-717, Hôpital Saint-Louis, AP-HP; Kheira Beldjord, Etienne Lengliné, and Hervé Dombret, University Paris 7, Hôpital Saint-Louis, AP-HP, and Institut Universitaire d'Hématologie, EA3518, Paris; Aline Tanguy-Schmidt and Norbert Ifrah, Pôle de Recherche et d'Enseignement Supérieur L'Université Nantes Angers Le Mans, Centre Hospitalier Universitaire Angers Service des Maladies du Sang et L'Institut National de la Santé et de la Recherche Médicale (INSERM) U892, Angers; Dominique Payet-Bornet and Bertrand Nadel, Center of Immunology of Marseille Luminy, Aix-Marseille University, INSERM U1104 and Centre National de la Recherche Scientifique (CNRS) UMR-7280, Marseille; Hossein Mossafa, Laboratoire Cerba, Cergy-Pontoise; Véronique Lhéritier and Xavier Thomas, Centre Hospitalier Lyon Sud, Lyon; Françoise Huguet, Hôpital Purpan, Toulouse; Thibaud Leguay, Centre Hospitalier du Haut Lévêque, Pessac; Jean-Yves Cahn, UMR-5525 CNRS-Université Joseph Fourier, Grenoble; Caroline Bonmati, Centre Hospitalier Régional Hôpital de Brabois, Vandoeuvre Les Nancy; Sebastien Maury, Hôpital Henry Mondor, Creteil, France; Yves Chalandon, University Hospital of Geneva, Geneva, Switzerland; and André Delannoy, Hopital de Jolimont, La Louviere, Belgium., Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengliné E, De Gunzburg N, Payet-Bornet D, Lhermitte L, Mossafa H, Lhéritier V, Bond J, Huguet F, Buzyn A, Leguay T, Cahn JY, Thomas X, Chalandon Y, Delannoy A, Bonmati C, Maury S, Nadel B, Macintyre E, Ifrah N, Dombret H, Asnafi V

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2013 Dec 01; Vol. 31 (34), pp. 4333-42. Date of Electronic Publication: 2013 Oct 28.